Previous 10 | Next 10 |
home / stock / esaly / esaly news
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries TOKYO, Mar 31, 2021 - (JCN Newswire) - KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Ei...
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan TOKYO, Mar 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc.,...
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab TOKYO, Mar 30, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the European Medicines...
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: ...
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: l...
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan TOKYO, Mar 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWA...
Eisai Awarded The New Diversity Management Selection 100 TOKYO, Mar 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selecti...
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders TOKYO, Mar 17, 2021 - (JCN Newswire) - Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have ent...
What do drugs for weight loss, pulmonary hypertension, and irritable bowel syndrome all have in common? Not much -- except they are all offerings in which Arena Pharmaceuticals (NASDAQ: ARNA) has come close to the finish line over the past two decades, only to come up short. IMA...
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu TOKYO, Mar 16, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibod...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...